NCT01446497

Efficacy and Safety Study of Combigan and 0.5% Timoptic in Normal Tension Glaucoma

Randomized, Multicenter, Open-label, Parallel Group Study to Evaluate Efficacy and Safety of Combigan(Brimonidine/Timolol) and 0.5% Timoptic(Timolol) Ophthalmic Solutions in Normal Tension Glaucoma Patients

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 22 (estimated)
• Sponsor: Seoul National University Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Purpose To evaluate efficacy and safety of combigan(Brimonidine/Timolol) and 0.5% Timoptic (Timolol) ophthalmic solutions in normal tension glaucoma patients.

Detailed description

* Normal tension glaucoma (NTG) is the major type of glaucoma in Korea. (over 90% of glaucoma type) * Brimonidine (selective alpha 2 adrenergic agonist): neuroprotection effect by suppression of aqueous humor production and increasement of uveoscleral outflow * Timolol (non selective beta blocker): suppression effect of aqueous humor production * Combigan (fixed combination of brimonidine \& timolol): more lowering effect of intraocular pressure and enhancing the compliance of glaucoma patients

Conditions

• Normal Tension Glaucoma

Interventions

Type	Name	Description
DRUG	Brimonidine/Timolol mixed combination	Twice per day, 1 drop at each time
DRUG	Timolol	Twice per day, 1 drop at each time

Timeline

• Start date: 2010-10-01
• Primary completion: 2011-08-01
• Completion: 2012-08-01
• First posted: 2011-10-05
• Last updated: 2011-10-05

Locations

1 site across 1 country: South Korea